RESEARCH ARTICLE

Multiplex Assay for Simultaneous Detection of *Mycoplasma genitalium* and Macrolide Resistance Using PlexZyme and PlexPrime Technology

Sepehr N. Tabrizi1,2,3*, Lit Y. Tan4, Samantha Walker4, Jimmy Twin1,2, Marin Poljak1,2, Catriona S. Bradshaw5,6, Christopher K. Fairley5,6, Melanie Bissessor5, Elisa Mokany4, Alison V. Todd4, Suzanne M. Garland1,2,3

1 Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, Victoria, Australia, 2 Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia, 3 Murdoch Childrens Research Institute, Parkville, Victoria, Australia, 4 SpeeDx Pty Ltd, Sydney, NSW, Australia, 5 Melbourne Sexual Health Centre, Carlton, Victoria, Australia, 6 Central Clinical School, Monash University, Victoria, Australia

* sepehr.tabrizi@thewomens.org.au

Abstract

*Mycoplasma genitalium* is a cause of non-gonococcal urethritis (NGU) in men and cervicitis and pelvic inflammatory disease in women. Recent international data also indicated that the first line treatment, 1 gram stat azithromycin therapy, for *M. genitalium* is becoming less effective, with the corresponding emergence of macrolide resistant strains. Increasing failure rates of azithromycin for *M. genitalium* has significant implications for the presumptive treatment of NGU and international clinical treatment guidelines. Assays able to predict macrolide resistance along with detection of *M. genitalium* will be useful to enable appropriate selection of antimicrobials to which the organism is susceptible and facilitate high levels of rapid cure. One such assay recently developed is the MG 23S assay, which employs novel PlexZyme™ and PlexPrime™ technology. It is a multiplex assay for detection of *M. genitalium* and 5 mutations associated with macrolide resistance. The assay was evaluated in 400 samples from 254 (186 males and 68 females) consecutively infected participants, undergoing tests of cure. Using the MG 23S assay, 83% (331/440) of samples were positive, with 56% of positives carrying a macrolide resistance mutation. Comparison of the MG 23S assay to a reference qPCR method for *M. genitalium* detection and high resolution melt analysis (HRMA) and sequencing for detection of macrolide resistance mutations, resulted in a sensitivity and specificity for *M. genitalium* detection and for macrolide resistance of 99.1/98.5% and 97.4/100%, respectively. The MG 23S assay provides a considerable advantage in clinical settings through combined diagnosis and detection of macrolide resistance.
Introduction

*Mycoplasma genitalium* was first isolated in 1980 from men with non-gonococcal urethritis (NGU) [1]. It has since been established as a common sexually transmitted infection responsible for 10–35% of non-chlamydial NGU in men [2] and also associated with cervicitis, endometritis, pelvic inflammatory disease (PID) and tubal factor infertility in women [3–7]. Studies also suggest *M. genitalium* plays an important role in HIV acquisition and transmission [8, 9].

Current recommended treatment for uncomplicated *M. genitalium* infection is a single 1 g oral dose of the macrolide antibiotic, azithromycin [10, 11]. In most developed countries, this is also the first line treatment for NGU. However cure rates following this treatment have declined to about 70% for genital *M. genitalium* infections, as macrolide resistance has emerged [12–14]. Macrolide resistance occurs through mutations in nucleotide positions 2058 and 2059 (E.coli numbering) in region V of the 23S rRNA gene, inhibiting binding of the macrolide to *M. genitalium* [14, 16]. An important limitation in current clinical practice is the ability to effectively treat this organism in a significant proportion of individuals, when prevalence of resistance to first line therapies is so high. To address this, a high resolution melt analysis (HRMA) methodology was recently described to rapidly detect 23S rRNA gene mutations associated with macrolide resistance in *M. genitalium* positive specimens [17]. This HRMA assay allowed for screening of 23S rRNA mutations; however it needs to be performed as a separate assay after *M. genitalium* detection, delaying results, second line treatment and potentiating further transmission.

Development of an assay for the simultaneous, rapid and sensitive detection of *M. genitalium* and mutations associated with macrolide resistance would offer an enormous clinical advantage, facilitating rapid delivery of the most appropriate therapy. This study evaluates the MG 23S assay, which employs novel PlexZyme™ and PlexPrime™ technology (SpeeDx), is a single well, multiplex qPCR assay, which simultaneously detects *M. genitalium* and five 23S rRNA mutations associated with macrolide resistance.

Methods

Patient population

The assay was evaluated using clinical samples previously screened for both *M. genitalium* detection by 16S rRNA qPCR and 23S rRNA mutation status by HRMA and Sanger sequencing. Between July 2012–June 2013, 400 specimens (including baseline, day 14 and/or day 28 specimens) from 254 consecutive *M. genitalium* infected participants (186 males (300 urine/urethral and 12 anal samples) and 68 females (41 urine, 42 cervical/vaginal and 5 anal samples)) were collected at Melbourne Sexual Health Centre, Victoria, Australia. This clinic conducts routine testing for *M. genitalium* in patients with NGU, cervicitis, and/or PID, as well as sexual contacts of *M. genitalium* infected patients. Ethical approval for this study was granted by the Alfred Hospital Research Ethics Committee (number 150/12).

Assay description

The MG 23S assay (SpeeDx Pty Ltd, Sydney, Australia) is a multiplex qPCR assay detecting across three fluorophore channels: 1) FAM (495–516) for detection of *M. genitalium* through detection of the *MgPa* gene, 2) Hex (535–556) for detection of 5 mutations that have been described in clinical samples (A2058G, A2059G, A2058C, A2059C and A2058T) in the 23S rRNA gene and 3) Cy5 (650–670) for detection of a heterologous extrinsic control to monitor extraction efficiency and qPCR inhibition. This assay employs novel PlexZyme (formerly known as MNAzyme) technology [18–20] and PlexPrimers which selectively amplify target sequences, coupled to enable high level multiplexing of mutant detection (Fig 1).
Quantified synthetic DNA templates from the MG 23S Positive Control (beta version) (SpeeDx) were utilized for the limit of detection testing of *M. genitalium* (*MgPa* gene) and mutations from the 23S rRNA gene; A2058G, A2059G, A2058C, A2059C and A2058T. Testing
of cross-reactivity of the MG 23S assay was performed with 10^4 copies of Amplirun® DNA (Vircell, Granada, Spain) for *Mycoplasma hominis* (Cat# MBC084), *Trichomonas vaginalis* (Cat# MBC079), *Chlamydia trachomatis* (Cat# MBC012), *Neisseria gonorrhoeae* (Cat# MBC075) and *Mycoplasma pneumoniae* (Cat# MBC035), and 10^5 copies of extracted DNA from clinical isolates of *Ureaplasma parvum* and *Ureaplasma urealyticum*. We have further tested extracted DNA from clinical isolates of further 24 unrelated species including *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Haemophilus influenzae*, *Enterococcus faecalis*, *Proteus mirabilis*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Candida albicans*, *Streptococcus pyogenes*, *Pseudomonas aeruginosa*, *Acinetobacter calcoaceticus*, *Neisseria gonorrhoeae*, *Bacteroides fragilis*, *E. coli*, *Viridans streptococci*, *Streptococcus Group A and B*, *Campylobacter jejuni*, *Neisseria meningitidis*, *Neisseria cinerea*, *Neisseria subflava*, *Neisseria lactamica*, *Chlamydophila pneumoniae* and *Chlamydia trachomatis*.

**Analytical Sensitivity**

The sensitivity of each of the targets of the MG 23S assay was determined as the lowest number of synthetic DNA template copies tested with ≥95% detection.

**Processing and PCR**

Samples were processed and extracted as described previously [12]. The reference method for detection of *M. genitalium* was an established qPCR assay targeting the 16S rRNA gene [21]. The reference standard for determining the presence of a mutation was HRMA and if any were unable to be determined using this method, the samples underwent sequencing of the region V of 23S rRNA as described previously [16, 17]. The MG 23S assay was performed as described by the manufacturer. Briefly, a 5 μl aliquot of the extracted DNA was mixed with Plex Master-mix in 20 μl final volume. All testing was performed in 96 well plates on the LightCycler® 480 Instrument II (Roche Diagnostic, Indianapolis, USA) using parameters of 95°C for 2 min, followed by 10 cycles of 95°C for 5 s, 61°C for 30 s (-0.5°C per cycle), and 40 cycles of 95°C for 5 s, 52°C for 40 s. Data analysis was performed using an analysis algorithm provided with the assay, resulting in reporting of the presence or absence of *M. genitalium*, any of the five mutations in the 23S rRNA gene, and the internal control. Controls for the assay were comprised of synthetic double stranded DNA targets for each 23S rRNA gene mutation type and *M. genitalium* G37 genomic DNA (ATCC 33530D) serving as the wild type and *M. genitalium* control.

**Results**

The limit of detection for the *M. genitalium* MgPa target was 10 copies. The limit of detection of 23S rRNA gene targets was 10 copies for A2058C, A2058T and A2059G, 12 copies for A2058G, and 15 copies for A2059C (Table 1). Cross-reactivity of primer and probe sequences

| Template | 10^5 | 10^4 | 10^3 | 10^2 | 10 | 1 | Copy number (detected/ replicates tested) |
|----------|------|------|------|------|----|---|----------------------------------------|
| A2058G   | 3/3  | 3/3  | 3/3  | 3/3  | 3/3| 2/3| 12 (20/20)                             |
| A2058C   | 3/3  | 3/3  | 3/3  | 3/3  | 3/3| 3/3| 10 (20/20)                             |
| A2058T   | 3/3  | 3/3  | 3/3  | 3/3  | 3/3| 1/3| 10 (19/20)                             |
| A2059G   | 3/3  | 3/3  | 3/3  | 3/3  | 3/3| 1/3| 12 (20/20)                             |
| A2059C   | 3/3  | 3/3  | 3/3  | 3/3  | 2/3| 0/3| 15 (20/20)                             |
| MgPa     | 3/3  | 3/3  | 3/3  | 3/3  | 3/3| 2/3| 10 (20/20)                             |

doi:10.1371/journal.pone.0156740.t001
for both MgPa and 23S rRNA were first analyzed in silico using BLAST to ensure specificity. Subsequent testing of the assay using DNA from related organisms and other clinically relevant organisms showed no cross-reacting agents for the MgPa assay or the 23S rRNA mutant assay.

Detection of \textit{M. genitalium} by the MG 23S assay was highly concordant (99.0%) with the reference method (qPCR targeting the 16S rRNA gene) with a Kappa value of 0.965 (95% confidence interval (CI) 0.930 to 0.999) and sensitivity/specificity of 99.1% and 98.5% respectively (Table 2). Only 4 (1.0%) of the specimens were discordant with one positive only by the MG 23S assay and 3 positive only by the reference assay. All of the discordant samples had low copy number of \textit{M. genitalium}. Among the 330 specimens positive for \textit{M. genitalium}, 325 (98.5%) were concordant for detection of a macrolide mutation, with a Kappa value of 0.969 (95% CI 0.942–0.996) and sensitivity/specificity of 97.4% and 100% respectively (Table 3). Only 5 cases with macrolide mutations detected by the reference method were classified as wild type by the MG 23S assay, and there were no cases with macrolide resistance detected by the MG 23S assay, where the reference method had shown a wild type status.

**Discussion**

Overall, the MG 23S assay showed excellent performance for the simultaneous detection of \textit{M. genitalium} and 23S rRNA mutations by qPCR, with high sensitivity and specificity compared to established gold standards.

Macrolide resistance is highly prevalent in \textit{M. genitalium} and exceeds 30% in many countries. As culture is difficult and rarely performed to allow performance of susceptibility testing, a molecular approach has been utilized to predict resistance to azithromycin. All azithromycin treatment failures to date have been shown to carry one of the five mutations in the 2058 and 2059 positions in the 23S rRNA gene \cite{12}, therefore detection of these mutations can be used

| Reference Assay\(^a\) | Sensitivity % (95% CI) / Specificity % (95% CI) |
|------------------------|-----------------------------------------------|
| PlexPCR                |                                               |
| Pos 330                | 99.1 (97.4–99.8) / 98.5 (92.0–100.0)         |
| Neg 3                  |                                               |
| Total 333              |                                               |

\(^a\) The reference assay for \textit{M. genitalium} detection was an in house qPCR assay targeting the 16S rRNA gene \cite{21}.

---

**Table 3. Evaluation of the MG 23S assay for the detection of 23S rRNA mutations.**

| Reference Assay\(^a\) | Sensitivity % (95% CI) / Specificity % (95% CI) |
|------------------------|-----------------------------------------------|
| PlexPCR                |                                               |
| MT\(^b\) 184          | 97.4 (93.9–99.1) / 100.0 (97.4–100.0)         |
| WT\(^b\) 5             |                                               |
| Total 189              |                                               |

\(^a\) The reference assay for 23S mutation status was HRMA and Sanger sequencing \cite{16, 17}.

\(^b\) MT refers to 5 common mutation detection of adenine to another base in 2058 or 2059 position of 23S rRNA. WT refers to adenine in both 2058 and 2059 positions of 23S rRNA.

\(^c\) Only includes \textit{M. genitalium} positive samples determined by reference method and excludes three samples in which 23S sequence status could not be confirmed.

---

\doi{10.1371/journal.pone.0156740.t002}

\doi{10.1371/journal.pone.0156740.t003}
to infer macrolide resistance. Molecular methodologies such as pyrosequencing, HRMA or FRET methods [17, 22] have been used to detect the presence of macrolide resistance mutations [23]. However these assays must be performed after the initial *M. genitalium* diagnostic test, delaying reporting of the mutation status. Other qPCR technologies are able to detect mutations such as mutation-specific primers and mutation-specific probes [24–26]. However, it is difficult to efficiently multiplex mutation-specific primers as they may only differ by a single base. Mutation-specific probes are also similarly limited in multiplexing due to competition. The novel design of the PlexPrimer overcomes this limitation by incorporating a unique sequence into the amplicon, to increase differentiation and reduce competition. PlexPrimers coupled with PlexZymes enables high level multiplexing, for specific mutation amplification and detection in qPCR.

The implementation of combined diagnostic and resistance testing to optimize rapid selection of more effective antimicrobials is considered a priority in the field. This would help to reduce recurrent clinical presentations to services, sequelae such as infertility, and secondary transmission of resistant strains. The MG 23S assay offers an enormous advantage in clinical settings, as it can be incorporated into clinical algorithms. Detection of 23S rRNA mutations would allow patients to be rapidly treated with an appropriate second line antibiotic such as the fluoroquinolone moxifloxacin, rather than waiting 3–4 weeks for a test of cure to show azithromycin treatment failure. Patients without evidence of macrolide resistance can currently be treated with azithromycin with high cure rates. There are however, up to 10% of patients that do not have detectable pre-treatment mutations, and appear to develop induced or selected resistance following azithromycin treatment. Treatment failure in these cases will not be avoided by the use of pre-treatment resistance assays. This will only be averted by the use of non-macrolide first line regimens; however identification of suitable alternatives has proven difficult. In addition to macrolides, *M. genitalium* is also developing resistance to moxifloxacin [12]. Development and inclusion of further markers for fluoroquinolone resistance would be greatly beneficial and is currently under development.

**Acknowledgments**

SpeeDx are the developer and manufacturer of the evaluated MG 23S assay and supplied the reagents utilized for this study.

**Author Contributions**

Conceived and designed the experiments: ST LT SW CB MB EM AT SG. Performed the experiments: ST MP JT LT. Analyzed the data: ST LT SW MP JT EM AT SG MB. Contributed reagents/materials/analysis tools: LT SW EM AT. Wrote the paper: ST LT SW JT MP CB CF SG AT EM MB.

**References**

1. Tully JG, Taylor-Robinson D, Cole RM, Rose DL. A newly discovered mycoplasma in the human urogenital tract. Lancet. 1981; 1(8233):1288–91. PMID: 6112607.
2. Horner PJ, Taylor-Robinson D. Association of Mycoplasma genitalium with balanoposthitis in men with non-gonococcal urethritis. Sex Transm Infect. 2011; 87(1):38–40. doi: 10.1136/sti.2010.044487 PMID: 20852310.
3. Cohen CR, Manhart LE, Bukusi EA, Astete S, Brunham RC, Holmes KK, et al. Association between Mycoplasma genitalium and acute endometritis. Lancet. 2002; 359(9308):765–6. doi: 10.1016/S0140-6736(02)07848-0 PMID: 11888591.
4. Deguchi T, Maeda S. Mycoplasma genitalium: another important pathogen of nongonococcal urethritis. J Urol. 2002; 167(3):1210–7. PMID: 11832700.
5. Jensen JS. Mycoplasma genitalium: the aetiological agent of urethritis and other sexually transmitted diseases. J Eur Acad Dermatol Venereol. 2004; 18(1):1–11. PMID: 14678525.

6. Taylor-Robinson D. Mycoplasma genitalium—an up-date. Int J STD AIDS. 2002; 13(3):145–51. PMID: 11860689.

7. Uusakula A, Kohl PK. Genital mycoplasmas, including Mycoplasma genitalium, as sexually transmitted agents. Int J STD AIDS. 2002; 13(2):79–85. PMID: 11839161.

8. Manhart LE, Mostad SB, Baeten JM, Astete SG, Mandaliya K, Totten PA. High Mycoplasma genitalium organism burden is associated with shedding of HIV-1 DNA from the cervix. J Infect Dis. 2008; 197(5):733–6. doi: 10.1086/526501 PMID: 18266605; PubMed Central PMCID: PMC4090222.

9. Mavedzenge SN, Van Der Pol B, Weiss HA, Kwok C, Mambo F, Chipato T, et al. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS. 2012; 26(5):617–24. doi: 10.1097/QAD.0b013e32834ff690 PMID: 22210630.

10. Shahmanesh M, Moi H, Lasau F, Janier M, Iusti/Who. 2009 European guideline on the management of male non-gonococcal urethritis. Int J STD AIDS. 2009; 20(7):458–64. doi: 10.1258/ijsa.2009.009143 PMID: 19541886.

11. Workowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03):1–137. PMID: 26042815.

12. Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015; 60(8):1228–36. doi: 10.1093/cid/ciu1162 PMID: 25537875.

13. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS One. 2008; 3(11):e3618. doi: 10.1371/journal.pone.0003618 PMID: 18978939; PubMed Central PMCID: PMC2572837.

14. Bradshaw CS, Jensen JS, Tabrizi SN, Read TR, Garland SM, Hopkins CA, et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis. 2006; 12(7):1149–52. doi: 10.3201/eid1207.051558 PMID: 16836839; PubMed Central PMCID: PMC3291056.

15. Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis. 2013; 56(7):934–42. doi: 10.1093/cid/cis1022 PMID: 23223595; PubMed Central PMCID: PMC3588116.

16. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008; 47(12):1546–53. doi: 10.1086/593188 PMID: 18990060.

17. Twin J, Jensen JS, Bradshaw CS, Garland SM, Fairley CK, Min LY, et al. Transmission and selection of macrolide resistant Mycoplasma genitalium infections detected by rapid high resolution melt analysis. PLoS One. 2012; 7(4):e35593. doi: 10.1371/journal.pone.0035593 PMID: 22532861; PubMed Central PMCID: PMC3331984.

18. Mokany E, Bone SM, Young PE, Doan TB, Todd AV. MNAzymes, a versatile new class of nucleic acid enzymes that can function as biosensors and molecular switches. J Am Chem Soc. 2010; 132(3):1051–9. doi: 10.1021/ja9076777 PMID: 20038095; PubMed Central PMCID: PMC2808728.

19. Mokany E, Tan YL, Bone SM, Fuery CJ, Todd AV. MNAzyme qPCR with superior multiplexing capacity. Clin Chem. 2013; 59(2):419–26. doi: 10.1373/clinchem.2012.192930 PMID: 23220665.

20. Mokany E, Todd AV. MNAzyme qPCR: a superior tool for multiplex qPCR. Methods Mol Biol. 2013; 1039:31–49. doi: 10.1007/978-1-62703-535-4_3 PMID: 24026684.

21. Twin J, Taylor N, Garland SM, Hocking JS, Walker J, Bradshaw CS, et al. Comparison of two Mycoplasma genitalium real-time PCR detection methodologies. J Clin Microbiol. 2011; 49(3):1140–2. doi: 10.1128/JCM.02328-10 PMID: 21209170; PubMed Central PMCID: PMC3067702.

22. Jensen JS. Protocol for the detection of Mycoplasma genitalium by PCR from clinical specimens and subsequent detection of macrolide resistance-mediating mutations in region V of the 23S rRNA gene. Methods Mol Biol. 2012; 903:129–39. doi: 10.1007/978-1-61779-937-2_8 PMID: 22782815.

23. Touali A, Peuchant O, Jensen JS, Bebear C, Pereyre S. Direct detection of macrolide resistance in Mycoplasma genitalium isolates from clinical specimens from France by use of real-time PCR and melting curve analysis. J Clin Microbiol. 2014; 52(5):1549–55. doi: 10.1128/JCM.03318-13 PMID: 24574291; PubMed Central PMCID: PMC3993663.

24. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 1999; 14(5–6):143–9. PMID: 10084106.
25. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989; 17(7):2503–16. PMID: 2785681; PubMed Central PMCID: PMC317639.

26. Tyagi S, Bratu DP, Kramer FR. Multicolor molecular beacons for allele discrimination. Nat Biotechnol. 1998; 16(1):49–53. doi: 10.1038/nbt0198-49 PMID: 9447593.
Author/s:
Tabrizi, SN; Tan, LY; Walker, S; Twin, J; Poljak, M; Bradshaw, CS; Fairley, CK; Bissessor, M; Mokany, E; Todd, AV; Garland, SM

Title:
Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology

Date:
2016-06-06

Citation:
Tabrizi, S. N., Tan, L. Y., Walker, S., Twin, J., Poljak, M., Bradshaw, C. S., Fairley, C. K., Bissessor, M., Mokany, E., Todd, A. V. & Garland, S. M. (2016). Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology. PLOS ONE, 11 (6), https://doi.org/10.1371/journal.pone.0156740.

Persistent Link:
http://hdl.handle.net/11343/259323

File Description:
Published version

License:
CC BY